טבע תציג נתונים אודות Fremanezumab בכנס של האגודה האמריקאית לכאבי ראש

פרסום "מתפרץ", שלוש מצגות פלטפורמה ו-23 פוסטרים עוסקים ב-fremanezumab, טיפול נסיוני למניעת מיגרנה

ירושלים, 28 ביוני 2018 – טבע תעשיות פרמצבטיות בע"מ (NYSE ו-TASE: TEVA) הודיעה היום על 23 תקצירים, פוסטר "מתפרץ" אחד ושלוש הרצאות בנושא fremanezumab לטיפול מונע של מיגרנה, אשר יוצגו בכנס המדעי השנתי של האגודה האמריקאית לכאבי ראש (AHS), שייערך בסן פרנסיסקו בין ה-28 ביוני עד ה-1 ביולי, 2018. זוהי הפעם הראשונה שבה ניתוחים בני שנה מלאה מוצגים עבור fremanezumab. הנתונים החדשים כוללים שיעורי תגובה, שימוש בתרופות חריפות לכאבי ראש ומוגבלות – על פני טווח ארוך. מצגות נתונים נוספות מתוך המחקרים הקליניים של fremanezumab בוחנות יעילות, בטיחות השפעה על איכות חיים ומעבר של מטופלים ממיגרנה כרונית לארעית. Fremanezumab הוא טיפול נסיוני הנמצא כעת תחת בחינת המינהל האמריקאי למזון ותרופות (FDA) כזריקה רבעונית או חודשית לטיפול מניעתי של מיגרנה בבוגרים.

"מיגרנה ממשיכה להיות מחלה מאתגרת עם צרכים משמעותיים שלא זוכים למענה בשל מיעוט של חידושים טיפוליים ב-25 שנה האחרונות," אמר ד"ר טושאר שאה, סמנכ"ל בכיר, ראש פיתוח קליני ועניינים רפואיים עבור תרופות ייחודיות בטבע. "טבע מחויבת לפתח טיפולים חדישים למטופלים הסובלים ממיגרנה וכאבי ראש. אנו שמחים לחלוק בכנס זה נתונים נוספים אודות fremanezumab, בעיקר אלו המבוססים על פני טווח ארוך, אשר הינו קריטי למטופלים."התקצירים שנתמכו על ידי טבע בכנס AHS כוללים את:

Late-Breaking Poster Presentation:

  • Response Over Time with Fremanezumab in the Treatment of Chronic and Episodic Migraine (Poster PF111)
    • Friday, June 29, poster Q&A, 1:15 - 2:15 pm PT

Platform Presentations:

  • The Impact of Fremanezumab on Medication Overuse in Patients with Chronic Migraine (IOR07)
  • Saturday, June 30, 8:00 am - 10:00 am PT
  • Presentation time: 9:00 am - 9:10 am PT
  • Response with Fremanezumab in the Treatment of Chronic Migraine (IOR11)
  • Saturday, June 30, 8:00 am - 10:00 am PT
  • Presentation time: 9:40 am - 9:50 am PT
  • Reversion of Patients with Chronic Migraine to an Episodic Migraine Classification with Fremanezumab Treatment (OR15)
  • Saturday, June 30, 2:15 pm - 3:45 pm PT
  • Presentation time: 2:15 pm - 2:25 pm PT
  • Long-Term Impact of Fremanezumab Posters (Yerba Buena Ballroom in the San Francisco Marriott Marquis):
  • Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine: Interim Results of a One-Year Study (Poster PF14)
  • Friday, June 29, 1:15 - 2:15 pm PT
  • Fremanezumab Long-Term Efficacy and Safety: Interim Results of a One-Year Study (Poster PS30)
  • Saturday, June 30, 1:15 - 2:15 pm PT
  • Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Interim Results of a One-Year Study (Poster PS35)
  • Saturday, June 30, 1:15 - 2:15 pm PT
  • Friday, June 29 Poster Sessions (Yerba Buena Ballroom in the San Francisco Marriott Marquis); presentations between 1:15 - 2:15 pm PT
  • Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Chronic Migraine (Poster PF08)
  • Efficacy of Fremanezumab in Patients with Chronic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA (Poster PF09)
  • The Impact of Fremanezumab on Headache-related Disability in Patients with Chronic Migraine Using the Headache Impact Test (HIT-6) (Poster PF12)
  • The Impact of Fremanezumab on Symptoms Associated with Migraine in Patients with Chronic Migraine (Poster PF15) 
  • Onset of Action with Fremanezumab versus Placebo for the Preventive Treatment of Chronic Migraine (Poster PF19) 
  • The Impact of Fremanezumab on Migraine-specific Health-related Quality of Life and Overall Health Status in Chronic Migraine (Poster PF23)
  • Efficacy of Fremanezumab on Migraine Frequency and Depression in Patients with Chronic Migraine and Comorbid Moderate to Moderately Severe Depression (Poster PF24) 
  • The Impact of Fremanezumab on Work Productivity and Activity Impairment in Patients with Chronic Migraine (Poster PF33) 
  • Onset of Action with Fremanezumab versus Placebo for the Preventive Treatment of Episodic Migraine (Poster PF43) 
  • Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Episodic Migraine (Poster PF44) 
  • Burden of Illness Among Treated Migraine Patients with ≥4 Headache Days in the past Month (Poster PF79) 
  • The Impact of Fremanezumab on Headache-related Disability in Patients with Episodic Migraine Using the Migraine Disability Assessment (Poster PF82) 
  • The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine (Poster PF87)
  • Saturday, June 30 Poster Sessions; (Yerba Buena Ballroom in the San Francisco Marriott Marquis); presentations between 1:00 - 2:15 pm PT
  • Relationship Between Fremanezumab Exposure and Efficacy in Preventive Therapy of Chronic Migraine in Adults (Poster PS31)
  • Relationship Between Fremanezumab Exposure and Efficacy in Preventive Therapy of Episodic Migraine in Adults (Poster PS32)
  • Efficacy of Fremanezumab in Patients with Episodic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA (Poster PS34) 
  • Overview of Fremanezumab Pooled Safety Data from Placebo-Controlled Phase 2 and 3 Studies (Poster PS40) 
  • Fremanezumab Cardiovascular Safety Profile: Pooled Data from Placebo-controlled and Long-term Studies (Poster PS41) 
  • Lack of Relationship Between Fremanezumab Exposure and Cardiovascular Adverse Events in Phase 2 and 3 Data Including Chronic and Episodic Migraine Patients (Poster PS47)
  • The Impact of Fremanezumab on Symptoms Associated with Migraine in Patients with Episodic Migraine (Poster PS59)
  • אודות Fremanezumab
  • Fremanezumab הוא טיפול נסיוני הנמצא כעת תחת בחינת המינהל האמריקאי למזון ותרופות (FDA) כזריקה רבעונית או חודשית לטיפול מניעתי של מיגרנה בבוגרים.

אודות טבע

טבע תעשיות פרמצבטיות בע"מ (NYSE & TASE: TEVA) היא חברת תרופות גלובלית המספקת פתרונות בריאות ממוקדי-מטופל באיכות גבוהה המשמשים מיליוני מטופלים מדי יום. טבע, שבסיסה בישראל, היא יצרנית התרופות הגנריות הגדולה בעולם, הממנפת את צבר מוצריה הכולל יותר מ-1,800 מולקולות לייצור מגוון רחב של מוצרים גנריים ברוב התחומים הטיפוליים. בתחום התרופות הייחודיות, לטבע יש עמדת הובלה בפיתוח טיפולים חדשניים למחלות של מערכת העצבים המרכזית, כולל כאב, וכן פורטפוליו מוצרים רחב בתחום הנשימה. טבע ממנפת את יכולותיה בגנריקה ובתרופות הייחודיות במטרה לחפש דרכים חדשות לענות על צרכי המטופלים, וזאת על ידי שילוב פיתוח תרופות יחד עם פיתוח תכשירים, שירותים וטכנולוגיות. הכנסות טבע בשנת 2017 הסתכמו ב-22.4$ מיליארד. למידע נוסף על החברה, בקרו באתר www.tevapharm.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

  • uncertainties relating to the potential benefits and success of our new structure and recent senior management changes as well as the potential success and our ability to effectively execute a restructuring plan;
  • our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”); our ability to realize the anticipated benefits of the acquisition (and any delay in realizing those benefits) or difficulties in integrating Actavis Generics; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our generic products, both from competing products and as a result of increased governmental pricing pressures; and our ability to take advantage of high-value biosimilar opportunities;
  • our specialty medicines business, including: competition for our specialty products, especially Copaxone®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights;
  • our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a downgrade of our credit ratings;
  • our business and operations in general, including: our ability to develop and commercialize additional pharmaceutical products; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel;the restructuring of our manufacturing network, including potential related labor unrest; the impact of continuing consolidation of our distributors and customers; variations in patent laws that may adversely affect our ability to manufacture our products; our ability to consummate dispositions on terms acceptable to us; adverse effects of political or economic instability, major hostilities or terrorism on our significant worldwide operations; and our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions;
  • compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; governmental investigations into sales and marketing practices; potential liability for sales of generic products prior to a final resolution of outstanding patent litigation; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
  • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; the significant increase in our intangible assets, which may result in additional substantial impairment charges; potentially significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;


and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. 

שתפו מאמר זה

למעבר לכל הכתבות והמאמרים

הקליקו כאן